Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 15561713 
Basak C, et al. (2005) NF-kappaB- and C/EBPbeta-driven interleukin-1beta gene expression and PAK1-mediated caspase-1 activation play essential roles in interleukin-1beta release from Helicobacter pylori lipopolysaccharide-stimulated macrophages. J Biol Chem 280, 4279-88 15561713
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S376-p - CASP1 (human)
Orthologous residues
CASP1 (human): S376‑p, CASP1 iso4 (human): S235‑p, CASP1 (mouse): S374‑p, CASP1 (rat): S374‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  THP1 (myeloid)
 Cellular systems studied:  cell lines
 Species studied:  human
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced

S9-p - GSK3B (human)
Orthologous residues
GSK3B (human): S9‑p, GSK3B iso2 (human): S9‑p, GSK3B (mouse): S9‑p, GSK3B (rat): S9‑p, GSK3B (rabbit): S3‑p
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LPS increase
wortmannin LPS inhibit treatment-induced increase

T180-p - P38A (human)
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LPS PAK1 (human) no change compared to control PAK1 WT
LPS PAK1 (human) no change compared to control PAC1 KD
LPS increase
wortmannin LPS inhibit treatment-induced increase
A-443654 LPS inhibit treatment-induced increase

Y182-p - P38A (human)
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LPS PAK1 (human) no change compared to control PAK1 WT
LPS PAK1 (human) no change compared to control PAC1 KD
LPS increase
wortmannin LPS inhibit treatment-induced increase
A-443654 LPS inhibit treatment-induced increase

S199-p - PAK1 (human)
Orthologous residues
PAK1 (human): S199‑p, PAK1 (mouse): S199‑p, PAK1 (rat): S198‑p
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LPS increase
wortmannin LPS inhibit treatment-induced increase
LPS increase
A-443654 LPS inhibit treatment-induced increase
wortmannin LPS inhibit treatment-induced increase
LPS Akt1 (human) increase
LPS increase
wortmannin LPS Akt1 (human) inhibit treatment-induced increase
LPS Akt1 (human) increase Akt1 WT
LPS LPS Akt1 (human) Akt1 (human) no effect upon treatment-induced increase Akt1 DN
LPS increase vector
LPS LPS RAC1 (human) inhibit treatment-induced increase Rac 1 DN

S204-p - PAK1 (human)
Orthologous residues
PAK1 (human): S204‑p, PAK1 (mouse): S204‑p, PAK1 (rat): S203‑p
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LPS increase
wortmannin LPS inhibit treatment-induced increase
LPS Akt1 (human) increase
LPS increase
wortmannin LPS Akt1 (human) inhibit treatment-induced increase
LPS Akt1 (human) increase Akt1 WT
LPS LPS Akt1 (human) Akt1 (human) no effect upon treatment-induced increase Akt1 DN
LPS increase vector
LPS LPS RAC1 (human) inhibit treatment-induced increase Rac 1 DN


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.